CAPHIV

"Early detection of HIV-1 using ultra-sensitive, rapid capacitive biosensor"

Coordinatore	ATEKNEA SOLUTIONS HUNGARY KFT    more  Organization address address: TETENYI UT 84-86 city: BUDAPEST postcode: 1119 contact info Titolo: Mr. Nome: Attila Cognome: Uderszky Email: send email Telefono: 3617874024 Fax: 3617874390
Nazionalità Coordinatore	Hungary [HU]
Totale costo	1˙280˙582 €
EC contributo	936˙500 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2011
Funding Scheme	BSG-SME
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-09-01   -   2013-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ATEKNEA SOLUTIONS HUNGARY KFT  Organization address address: TETENYI UT 84-86 city: BUDAPEST postcode: 1119 contact info Titolo: Mr. Nome: Attila Cognome: Uderszky Email: send email Telefono: 3617874024 Fax: 3617874390	HU (BUDAPEST)	coordinator	39˙460.00
2	LIONEX GMBH  Organization address address: Salzdahlumer Strasse 196 city: BRAUNSCHWEIG postcode: 38126 contact info Titolo: Dr. Nome: Mahavir Cognome: Singh Email: send email Telefono: +49 5312601266 Fax: +49 5312601159	DE (BRAUNSCHWEIG)	participant	272˙720.00
3	CAPSENZE HANDELSBOLAG  Organization address address: ANNEBERGS GARD 5520 city: BILLEBERGA postcode: 26021 contact info Titolo: Dr. Nome: Martin Cognome: Hedström Email: send email Telefono: 46418431435	SE (BILLEBERGA)	participant	236˙600.00
4	AB BCN S.L.  Organization address address: LG BELLATERRA PARC DE RECERCA city: CERDANYOLA DEL VALLES postcode: 8193 contact info Titolo: Ms. Nome: Marina Cognome: Azor Alastuey Email: send email Telefono: +34 935868984 Fax: +34 902107751	ES (CERDANYOLA DEL VALLES)	participant	194˙330.00
5	PHENOSYSTEMS SA  Organization address address: SENTIER DES COMMUNS 1 city: BLONAY postcode: 1807 contact info Titolo: Dr. Nome: David Cognome: Atlan Email: send email Telefono: +41 22 548 1400	CH (BLONAY)	participant	169˙720.00
6	LUNDS UNIVERSITET  Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Dr. Nome: Maria Cognome: Andersson Email: send email Telefono: 46462223673 Fax: 46462224713	SE (LUND)	participant	23˙670.00
7	FIMA SRL  Organization address address: VIA A VANZETTI 43 city: TERNI postcode: 5100 contact info Titolo: Dr. Nome: Elisabetta Cognome: Mauri Email: send email Telefono: +39 0744306716 Fax: 390744000000	IT (TERNI)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The HIV pandemic continues to be a worldwide public-health problem. The virus, which is spread through sexual contact, exposure to infected blood, or through shared syringes, is highly infective, rapidly mutates, and has no cure. Because there is no effective vaccine or other prophylaxis available, the current best practice and standard of care for those infected is an early, accurate diagnosis for the presence of HIV followed by immediate treatment on antiretroviral therapies and counseling. The most commonly used and widely accessible diagnostic tests and assays rely on the presence of HIV antibodies, but the window period before seroconversion takes place to produce these antibodies in the host can take up to six months. Moreover, newborns cannot be tested with these methods due to maternal antibodies masking their true HIV status. Thus, antibody-detecting approaches have major shortcomings in incidence and infant testing, which are critical components to early treatment and reduced transmission rates. Diagnostic tests targeting antibodies or nucleic acids are also susceptible to false or discordant results due to viral variations.

Hence, of particular interest as a target then is the conserved viral capsid protein, p24 antigen. Under certain conditions, antigen assays can achieve sensitivities that nearly match those of NATs without the need for amplification steps, and the antigen has a much shorter window period than the antibody, allowing it to be much more effective at incidence and infant testing.'

Introduzione (Teaser)

The CAPHIV project has potentially revolutionised HIV detection by delivering a novel biosensor system that could be applied at point-of-care for HIV screening.